Cytonics Corp

Invest in Cytonics stock and own a piece of a long-needed solution to a $560B+ condition affecting 500M+ worldwide.

  • Raising on DealMaker
  • Equity
  • United States

The raise in figures

Maximum

US$49,400,000

Last updated

↳ DealMaker · checked 3 min ago

About this raise

DealMaker lists Cytonics Corp as an upcoming equity crowdfunding raise. It is a company based in the United States. Investors are offered preferred shares under Regulation A+ (Reg A+).

Cytonics Corp set a maximum of $49.4M.

A Reg A+ offering is open to the general public, but only after the SEC has qualified its offering statement. With shares, investors own a part of Cytonics Corp. These figures are DealMaker’s own, as Raise Sonar last read them on . Money goes through DealMaker, not through Raise Sonar, which doesn’t handle investments.

Upcoming

Opens on DealMaker

Funding history

No amount reserved has been reported for Cytonics Corp yet, so there’s no history to draw.

About Cytonics Corp

Summarised by Raise Sonar from Cytonics Corp’s DealMaker pitch

Cytonics is developing CYT-108, a genetically engineered variant of the natural A2M protein, as a potential disease-modifying therapy for osteoarthritis. The therapy is designed to inhibit cartilage-destroying proteases and repair cartilage when delivered directly into the joint. CYT-108 has cleared Phase 1 human trials and the company is advancing toward Phase 1b/2a studies.

Read the full pitch on DealMaker (opens in a new tab)

More like this

More raises on DealMaker

All DealMaker raises

Live now

Opening soon

About Raise Sonar

Every live equity crowdfunding raise, in one place

We track raises across Crowdcube, Republic, Wefunder, StartEngine and more, and tell you when they open and before they close.

  • Launch alerts

    An email when a raise matching your filters opens.

  • Close reminders

    Follow a raise and hear from us 72 and 24 hours before it closes.

  • One search, every platform

    Filter live raises by sector, country, minimum and platform.

  • The weekly newsletter

    New raises and raises closing soon, every Monday.